Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. senior vice president and general counsel Henry Lee Chan reported a mix of equity transactions. He sold 428 American Depositary Shares at $257.635 per ADS pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
He also acquired 45,071 Ordinary Shares underlying restricted share units that vest over four years starting on June 11, 2026, with 1/4 vesting on each anniversary, subject to continued service. In addition, he received a share option for 87,308 Ordinary Shares at an exercise price of $20.81 per share, expiring on June 10, 2036, vesting 25% on the first anniversary of June 11, 2026 and monthly thereafter. Following these transactions, he directly holds 346,554 Ordinary Shares and 87,308 options.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported a mix of equity awards and routine share sales related to tax withholding. He received 177,931 Ordinary Shares underlying restricted share units, scheduled to vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon a change of control or certain termination events.
Oyler also received a share option covering 344,669 Ordinary Shares at an exercise price of $20.8100 per share, vesting over four years on a similar schedule. The filing shows open‑market sales totaling 1,949 American Depositary Shares at weighted average prices around $256–$259; these were effected under a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each American Depositary Share represents 13 Ordinary Shares. Several large blocks of Ordinary Shares are held indirectly through trusts, an LLC, and a Roth IRA account, and the filing states that Oyler disclaims beneficial ownership of multiple indirect holdings.
BeOne Medicines Ltd. director and scientific advisory board chair Xiaodong Wang reported new equity awards. He received 99,892 Ordinary Shares at a price of $0.00 per share, bringing his direct holdings to 4,682,493 Ordinary Shares after the award.
Wang was also granted a share option for 193,492 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. The footnotes state that these option shares vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder in 36 monthly installments, subject to continued service. Additional Ordinary Shares are held indirectly by a family trust, Wang Investment LLC, and Wang’s spouse, for which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
BRANDICOURT OLIVIER reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Olivier Brandicourt received a grant of 18,980 Ordinary Shares in the form of restricted share units on June 11, 2026 at no cash cost, as director compensation. These restricted share units vest in full on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Brandicourt directly holds 46,306 Ordinary Shares.
HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Anthony C. Hooper received an equity grant of 18,980 Ordinary Shares in the form of restricted share units at no cash cost on 2026-06-11. These restricted share units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Hooper holds 83,720 Ordinary Shares directly.
Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares on a Form 4 filing. These shares underlie restricted share units granted at a price of $0.00 per share as a compensation award rather than a market purchase.
The restricted share units will become fully vested on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless accelerated under the company’s Independent Non-Executive Director Compensation Policy.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Margaret Dugan received an equity award of 18,980 Ordinary Shares on June 11, 2026, reported at a price of $0.0000 per share. These represent securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Dugan directly holds 73,164 Ordinary Shares.
Sawyers Charles Lazelle reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Charles Lazelle Sawyers reported a grant of 18,980 Ordinary Shares as a share-based award. The award represents restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting triggers under the company’s Independent Non-Executive Director Compensation Policy. Following the award, he holds 18,984 Ordinary Shares directly. A separate entry shows 1,946 American Depositary Shares held directly, and each American Depositary Share represents 13 Ordinary Shares.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Shalini Sharp reported a compensation-related equity award. She received 18,980 Ordinary Shares for no cash payment, described as securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and possible accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. After this award, she directly holds 38,116 Ordinary Shares. A separate line shows direct ownership of 9 American Depositary Shares, with each American Depositary Share representing 13 Ordinary Shares.
Riva Alessandro reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Alessandro Riva received a grant of 18,980 ordinary shares in the form of restricted share units at no purchase price. These units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to his continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Riva directly holds 73,164 ordinary shares.